...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>American Journal of Veterinary Research >Pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or intravenous infusion of penciclovir
【24h】

Pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or intravenous infusion of penciclovir

机译：口服泛昔洛韦或静脉注射喷昔洛韦后，喷昔洛韦在健康猫体内的药代动力学

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective-To investigate the pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or IV infusion of penciclovir. Animals-6 cats. Procedures-Cats received famciclovir (40 [n = 3] or 90 [3] mg/kg, PO, once) in a balanced crossover-design study; the alternate dose was administered after a >= 2-week washout period. After another washout period (>= 4 weeks), cats received an IV infusion of penciclovir (10 mg/kg delivered over 1 hour). Plasma penciclovir concentrations were analyzed via liquid chromatography mass spectrometry at fixed time points after drug administration. Results-Mean +/- SD maximum plasma concentration (C-max) of penciclovir following oral administration of 40 and 90 mg of famciclovir/kg was 1.34 +/- 0.33 mu g/mL and 1.28 +/- 0.42 mu g/mL and occurred at 2.8 +/- 1.8 hours and 3.0 +/- 1.1 hours, respectively; penciclovir elimination half-life was 4.2 +/- 0.6 hours and 4.8 +/- 1.4 hours, respectively; and penciclovir bioavailability was 12.5 +/- 3.0% and 70 +/- 1.8%, respectively. Following IV infusion of penciclovir (10 mg/kg), mean +/- SD penciclovir clearance, volume of distribution, and elimination half-life were 4.3 +/- 0.8 mL/min/kg, 0.6 +/- 0.1 L/kg, and 1.9 +/- 0.4 hours, respectively. Conclusions and Clinical Relevance-Penciclovir pharmacokinetics following oral administration of famciclovir were nonlinear within the dosage range studied, likely because of saturation of famciclovir metabolism. Oral administration of famciclovir at 40 or 90 mg/kg produced similar C-max and time to C-max values. Therefore, the lower dose may have similar antiviral efficacy to that proven for the higher dose. (Am J Vet Res 2012;73:1092-1099)
机译：目的-研究泛昔洛韦或静脉注射喷昔洛韦后喷昔洛韦在健康猫体内的药代动力学。动物6只猫。程序-在平衡的交叉设计研究中，猫接受泛昔洛韦（40 [n = 3]或90 [3] mg / kg，一次，一次）;在> = 2周的清除期后给予替代剂量。在另一个冲洗期（> = 4周）后，猫接受了喷昔洛韦的静脉输注（10 mg / kg在1小时内递送）。在给药后的固定时间通过液相色谱质谱法分析血浆喷昔洛韦浓度。结果-口服40毫克和90毫克泛昔洛韦/公斤后喷昔洛韦的平均+/- SD最大血浆浓度（C-max）为1.34 +/- 0.33μg / mL和1.28 +/- 0.42μg / mL和分别发生在2.8 +/- 1.8小时和3.0 +/- 1.1小时;喷昔洛韦消除半衰期分别为4.2 +/- 0.6小时和4.8 +/- 1.4小时;喷昔洛韦的生物利用度分别为12.5 +/- 3.0％和70 +/- 1.8％。静脉注射喷昔洛韦（10 mg / kg）后，喷昔洛韦的平均+/- SD清除率，分布体积和消除半衰期分别为4.3 +/- 0.8 mL / min / kg，0.6 +/- 0.1 L / kg，和1.9 +/- 0.4小时。结论和临床相关性-口服泛昔洛韦后服用泛昔洛韦的药代动力学在所研究的剂量范围内是非线性的，可能是由于泛昔洛韦的代谢饱和所致。以40或90 mg / kg口服泛昔洛韦产生的C-max和达到C-max值的时间相似。因此，较低的剂量可能具有与较高剂量相同的抗病毒功效。 （Am J Vet Res 2012; 73：1092-1099）

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号